Boston Scientific Corporation $BSX Shares Bought by Amundi

Key Points

• Amundi increased its Boston Scientific stake by 1.2% in the second quarter, acquiring 173,208 additional shares and bringing its holdings to 14.3 million shares, valued at approximately $610.2 million.
• Institutional investors own 89.07% of Boston Scientific, with BlackRock and California State Teachers Retirement System among the major recent buyers. Analysts maintain a “Moderate Buy” consensus and an average price target of $71.62.
• Boston Scientific exceeded quarterly expectations with $0.86 in EPS and $5.44 billion in revenue, while its board authorized a $5 billion share-buyback program. Cyberattack-related shipping disruptions and product recalls remain key risks.

Amundi lifted its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 1.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,296,121 shares of the medical equipment provider's stock after acquiring an additional 173,208 shares during the period. Amundi owned 0.99% of Boston Scientific worth $610,158,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Boston Scientific during the second quarter worth approximately $5,534,781,000. California State Teachers Retirement System boosted its stake in shares of Boston Scientific by 4,113.5% during the 2nd quarter. California State Teachers Retirement System now owns 96,909,037 shares of the medical equipment provider's stock worth $4,136,078,000 after acquiring an additional 94,609,083 shares in the last quarter. State Street Corp grew its holdings in shares of Boston Scientific by 1.4% in the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider's stock worth $6,278,422,000 after acquiring an additional 920,495 shares during the last quarter. Primecap Management Co. CA acquired a new stake in shares of Boston Scientific during the second quarter worth $2,156,233,000. Finally, Capital World Investors raised its position in shares of Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider's stock worth $2,588,953,000 after purchasing an additional 502,627 shares during the period. Institutional investors own 89.07% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on BSX. BTIG Research cut their price objective on Boston Scientific from $65.00 to $60.00 and set a "buy" rating on the stock in a report on Wednesday, July 29th. Barclays cut their price target on shares of Boston Scientific from $96.00 to $89.00 and set an "overweight" rating on the stock in a report on Thursday, May 28th. Bank of America lowered their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a "buy" rating on the stock in a research report on Monday, May 18th. Royal Bank Of Canada decreased their target price on Boston Scientific from $85.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, July 30th. Finally, Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $60.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $71.62.

Insider Buying and Selling

In other Boston Scientific news, Director Edward J. Ludwig acquired 5,000 shares of the business's stock in a transaction that occurred on Friday, July 31st. The shares were acquired at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the acquisition, the director directly owned 30,359 shares of the company's stock, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David C. Habiger bought 2,100 shares of the stock in a transaction on Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 194,522 shares of company stock worth $9,385,210 in the last three months. Insiders own 0.34% of the company's stock.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Shipping operations are being restored after a cyberattack. Boston Scientific has begun resuming product shipments, suggesting the disruption may be contained and reducing concerns about a prolonged impact on revenue and customer relationships. Boston Scientific begins to restore shipping after cyberattack
• Positive Sentiment: Interventional cardiology and vascular therapy growth remains a key support. ICVT sales reportedly increased 15%, helped by demand for coronary therapies, new devices and strategic deals. Sustained momentum in this business could help offset pressure elsewhere. Boston Scientific's ICVT Business Gains Momentum
• Positive Sentiment: Clinical progress may expand the heart-failure opportunity. The completion of the LUX-Dx TRENDS study provides additional data on Boston Scientific’s implantable monitoring technology, although the commercial impact depends on study results and adoption. Boston Scientific’s LUX-Dx TRENDS Study
• Neutral Sentiment: Heavy call-option activity indicates some traders are positioning for a rebound, but options flows do not guarantee future stock performance. Stock Traders Buy High Volume of Call Options on Boston Scientific
• Negative Sentiment: Product recalls remain a significant overhang. Boston Scientific recalled Infinion CX spinal-cord-stimulator leads because of fracture risk following 1,081 injury reports, while additional worldwide recalls could increase costs, regulatory scrutiny and liability exposure. Boston Scientific Recalls Spinal Cord Stimulator Leads
• Negative Sentiment: The cyberattack disrupted shipments, and concerns about weaker 2026 guidance and broader business pressure have weighed on the outlook. The recent decline before the latest recovery reflects investor caution despite Boston Scientific’s prior earnings and revenue beats. Cyberattack and Weak 2026 Outlook Weigh on BSX

Boston Scientific Price Performance

NYSE BSX opened at $47.85 on Monday. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The stock's 50-day moving average is $46.90 and its two-hundred day moving average is $55.60. The firm has a market cap of $69.35 billion, a P/E ratio of 19.37, a price-to-earnings-growth ratio of 1.10 and a beta of 0.57. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter last year, the company posted $0.75 earnings per share. The company's revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has initiated a share buyback program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's management believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source